ConductScience.org, home

Comparison · NCT00619918-321cc3c0

Nebulized 3% Saline vs Nebulized 0.9% Saline: Number of Participants With Supplemental Medication Use

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Nebulized 3% Saline vs Nebulized 0.9% Saline: Number of Participants With Supplemental Medication Use. Trial comparisons, record NCT00619918-321cc3c0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00619918-321cc3c0

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1690.1260.222wilson
Risk in group 20.1810.1350.237wilson
Risk difference, group 1 minus group 2-0.0117-0.08280.0587newcombe hybrid score
Risk ratio, group 1 over group 20.9350.6251.4log
Odds ratio, group 1 over group 20.9220.5661.5log
Number needed to treat, for one fewer participant with the outcome on Nebulized 3% Saline than on Nebulized 0.9% Saline85.3from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Nebulized 3% Saline3% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting.~Nebulized 3% saline: 4 ml inhaled q8h39231OG000
Group 2Nebulized 0.9% Saline0.9% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting.~Nebulized 0.9% saline: normal saline39216OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Supplemental Medication Use
Description
patients who received supplemental albuterol, ipratropium, or epinephrine inhaled treatment (other than pre-treatment for study med)
Time frame
14 days
Population
230 patients were allocated to the 3% group; one patient allocated to the 0.9% group received 3% so was added to the 3% group for analysis, totaling 231 patients. The 0.9% group originally had 217 patients but after moving this patient to the 3% group, there are now 216 patients in the 0.9% group.

Source ClinicalTrials.gov

Trial

Title
Nebulized Hypertonic Saline for Bronchiolitis
NCT number
NCT00619918
Phases
PHASE2, PHASE3
Conditions
Bronchiolitis
Interventions
Nebulized 3% saline, Nebulized 0.9% saline
Lead sponsor
Children's Hospital Los Angeles
Results first posted
2013-10-10

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00619918-321cc3c0